PT Kimia Farma Tbk, (KAEF) Fair Value & Analysis
Healthcare · ID · Market cap 2.3T IDR
Fair value as of: Jun 24, 2026
Analysis
PT Kimia Farma Tbk, (KAEF) currently trades at 478.00 IDR, while our model-based Fair Value estimate is 320.14 IDR — implying the stock looks roughly 33.0% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
PT Kimia Farma Tbk, together with its subsidiaries, manufactures and sells a range of medicines in Indonesia and internationally. It operates through Manufacture, Distribution, Retail, and Others segments. The company offers drugs in the form of tablets, effervescent tablets, hard and soft capsules, liquids, syrups, oral powders, non-beta-lactam external liquids, beta-lactam tablets and dry syrups, injections, ointments, creams, suppositories, semisolid dosage forms, and health supplements; traditional medicines; generic drugs, such as paracetamol, amoxicillin, and omeprazole; ethical products; over-the-counter products and herbs; and narcotic drugs and psychotropics. It also provides health food; cosmetics; edible, castor, and essential oils; active pharmaceutical ingredients and high-function chemicals; quinine salt and its derivatives; antiseptic solutions; stem cells; and medical devices. In addition, the company engages in the provision of integrated health services, including …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is PT Kimia Farma Tbk, (KAEF) undervalued?
What is the fair value of KAEF?
What is the quality score of KAEF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.